Department of Epidemiology, University of Washington, Seattle.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
JAMA Netw Open. 2021 Apr 1;4(4):e214514. doi: 10.1001/jamanetworkopen.2021.4514.
Sepsis disproportionately affects recipients of allogeneic hematopoietic cell transplant (allo-HCT), and timely detection is crucial. However, the atypical presentation of sepsis within this population makes detection challenging, and existing clinical sepsis tools have limited prognostic value among this high-risk population.
To develop a full risk factor (demographic, transplant, clinical, and laboratory factors) and clinical factor-specific automated bacterial sepsis decision support tool for recipients of allo-HCT with potential bloodstream infections (PBIs).
DESIGN, SETTING, AND PARTICIPANTS: This prognostic study used data from adult recipients of allo-HCT transplanted at the Fred Hutchinson Cancer Research Center, Seattle, Washington, between June 2010 and June 2019 randomly divided into 70% modeling and 30% validation data sets. Tools were developed using the area under the curve (AUC) optimized SuperLearner, and their performance was compared with existing clinical sepsis tools: National Early Warning Score (NEWS), quick Sequential Organ Failure Assessment (qSOFA), and Systemic Inflammatory Response Syndrome (SIRS), using the validation data set. Data were analyzed between January and October of 2020.
The primary outcome was high-sepsis risk bacteremia (culture confirmed gram-negative species, Staphylococcus aureus, or Streptococcus spp bacteremia), and the secondary outcomes were 10- and 28-day mortality. Tool discrimination and calibration were examined using accuracy metrics and expected vs observed probabilities.
Between June 2010 and June 2019, 1943 recipients of allo-HCT received their first transplant, and 1594 recipients (median [interquartile range] age at transplant, 54 [43-63] years; 911 [57.2%] men; 1242 individuals [77.9%] identifying as White) experienced at least 1 PBI. Of 8131 observed PBIs, 238 (2.9%) were high-sepsis risk bacteremia. Compared with high-sepsis risk bacteremia, the full decision support tool had the highest AUC (0.85; 95% CI, 0.81-0.89), followed by the clinical factor-specific tool (0.72; 95% CI, 0.66-0.78). SIRS had the highest AUC of existing tools (0.64; 95% CI, 0.57-0.71). The full decision support tool had the highest AUCs for PBIs identified in inpatient (0.82; 95% CI, 0.76-0.89) and outpatient (0.82; 95% CI, 0.75-0.89) settings and for 10-day (0.85; 95% CI, 0.79-0.91) and 28-day (0.80; 95% CI, 0.75-0.84) mortality.
These findings suggest that compared with existing tools and the clinical factor-specific tool, the full decision support tool had superior prognostic accuracy for the primary (high-sepsis risk bacteremia) and secondary (short-term mortality) outcomes in inpatient and outpatient settings. If used at the time of culture collection, the full decision support tool may inform more timely sepsis detection among recipients of allo-HCT.
败血症在异基因造血细胞移植(allo-HCT)受者中不成比例地发生,及时发现至关重要。然而,该人群中败血症的非典型表现使得检测具有挑战性,并且现有的临床败血症工具在这个高风险人群中的预后价值有限。
为潜在血流感染(PBIs)的 allo-HCT 受者开发一个全风险因素(人口统计学、移植、临床和实验室因素)和临床因素特异性自动细菌性败血症决策支持工具。
设计、地点和参与者:这项预后研究使用了 2010 年 6 月至 2019 年 6 月期间在华盛顿州西雅图的弗雷德·哈钦森癌症研究中心接受 allo-HCT 的成年受者的数据,这些受者随机分为 70%的建模和 30%的验证数据集。使用 AUC(曲线下面积)优化的 SuperLearner 开发工具,并使用验证数据集比较其与现有临床败血症工具(NEWS、快速序贯器官衰竭评估(qSOFA)和全身炎症反应综合征(SIRS))的性能。数据分析于 2020 年 1 月至 10 月进行。
主要结局是高脓毒症风险菌血症(培养证实的革兰氏阴性菌、金黄色葡萄球菌或链球菌属菌血症),次要结局是 10 天和 28 天死亡率。使用准确性指标和预期与观察到的概率来检查工具的区分度和校准度。
2010 年 6 月至 2019 年 6 月期间,1943 名 allo-HCT 受者接受了他们的第一次移植,其中 1594 名受者(移植时的中位数[四分位数范围]年龄,54[43-63]岁;911[57.2%]名男性;1242 名[77.9%]个体认定为白人)经历了至少一次 PBI。在 8131 例观察到的 PBIs 中,238 例(2.9%)为高脓毒症风险菌血症。与高脓毒症风险菌血症相比,全决策支持工具的 AUC 最高(0.85;95%CI,0.81-0.89),其次是临床因素特异性工具(0.72;95%CI,0.66-0.78)。SIRS 具有现有工具中最高的 AUC(0.64;95%CI,0.57-0.71)。全决策支持工具在住院(0.82;95%CI,0.76-0.89)和门诊(0.82;95%CI,0.75-0.89)环境中识别的 PBIs 以及 10 天(0.85;95%CI,0.79-0.91)和 28 天(0.80;95%CI,0.75-0.84)死亡率方面具有最高的 AUC。
这些发现表明,与现有工具和临床因素特异性工具相比,全决策支持工具在住院和门诊环境中对主要(高脓毒症风险菌血症)和次要(短期死亡率)结局具有更高的预后准确性。如果在培养采集时使用,全决策支持工具可能会在 allo-HCT 受者中更早地发现败血症。